SCHEMBL10246598

SCHEMBL10246598

C=C(C)CN1CCOCC1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
HSD17B10 Q99714 3/20 0.50
ALOX15 P16050 2/20 0.48
TSHR P16473 1/20 0.48
SMN1; SMN2 Q16637 5/20 0.45
USP2 O75604 1/20 0.43
ALDH1A1 P00352 4/20 0.41
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
GLA P06280 1/20 0.38
STAT6 P42226 1/20 0.37
LMNA P02545 1/20 0.37
KEAP1 Q14145 1/20 0.37
OPRD1 P41143 1/20 0.37
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10246602 0.82
SCHEMBL7281285 0.80 KDM4E (0.54) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL70060 0.80 KDM4E (0.54) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL7229572 0.80 KDM4E (0.54) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL16016389 0.79 KDM4E (0.53) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL20327046 0.79 KDM4E (0.53) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL11564268 0.78 KDM4E (0.40) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL11561471 0.78 KDM4E (0.40) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL12247553 0.78 KDM4E (0.52) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2
SCHEMBL27339631 0.78 HSD17B10 (0.58) KDM4EHSD17B10ALOX15TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116014240-A Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same 三菱化学株式会社 2023-04-25 CN disclosed
WO-2022036123-A1 METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME SPRUCE BIOSCIENCES, INC. (US) 2022-02-17 WO disclosed
WO-2014100719-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-06-26 WO disclosed
US-20120041193-A1 SUBSTITUTED INTERNAL VINYL-BORONIC ACIDS AND BORONIC ACID DERIVATIVES FRONTIER SCIENTIFIC, INC. (US) 2012-02-16 US disclosed
US-7928099-B2 Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists PFIZER INC (US) 2011-04-19 US disclosed
US-20100113422-A1 Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists ANDREWS MARK 2010-05-06 US disclosed
EP-0079842-B1 ACRYLIC COPOLYMERS BASED ON N-ACRYLYLPOLYMETHYLENE IMINES OR N-ACRYLYLDIALKYL AMIDES, N,N'-ACRYLYLDIAMINO ALCANES AND N-ACRYLYLAMINO ACIDS (OR ESTERS), THEIR PREPARATION AND THEIR USE AS CATION EXCHANGERS Société d'Expansion Scientifique Expansia (FR) 1985-08-14 EP disclosed
US-4526932-A Copolymer containing N-coordinated triorganotin compound NITTO KASEI CO., LTD. (JP) 1985-07-02 US disclosed
EP-0079842-A1 Acrylic copolymers based on N-acrylylpolymethylene imines or N-acrylyldialkyl amides, N,N'-acrylyldiamino alcanes and N-acrylylamino acids (or esters), their preparation and their use as cation exchangers Société d'Expansion Scientifique Expansia (FR) 1983-05-25 EP disclosed
US-4059581-A Heterocyclic nitrogen containing siloxanes UNION CARBIDE CORPORATION (US) 1977-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041193-A1 SUBSTITUTED INTERNAL VINYL-BORONIC ACIDS AND BORONIC ACID DERIVATIVES BLVRB, BTD, BCL6B KDM4E 3155/4885HSD17B10 2088/4885ALOX15 2674/4885
US-20100113422-A1 Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists HTR2C, HTR2A, HTR5A KDM4E 2290/4885HSD17B10 1813/4885ALOX15 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.